Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.

Episode metadata supplied by the publisher feed · Published Nov 12, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

0:00 5:11

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 5 minutes long.

When was this BiotechTV - News episode published?

This episode was published on November 12, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!